Last reviewed 2026-05-21 · How we verify

Tazanol (TAZANOLAST)

Phase 2 active Small molecule ✓ Verified May 2026 Quality 19/100

Tazanol (generic name: TAZANOLAST) is a tazanolast drug. It is currently in Phase 2 development for Allergic conjunctivitis.

Tazanolast works by inhibiting the action of a specific enzyme involved in the allergic response.

Tazanol is a small molecule. It is also known by the synonyms TAZANOL and TAZANOLAST.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TAZANOLAST
Drug class	tazanolast
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

Think of it like a fire alarm in your house. When there's a fire, the alarm goes off to alert you. In allergic conjunctivitis, the 'fire' is an overactive immune response. Tazanolast is like a fire extinguisher that helps turn off the alarm, reducing the symptoms of the allergic reaction.

Approved indications

Allergic conjunctivitis

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tazanol CI brief — competitive landscape report
Tazanol updates RSS · CI watch RSS

Frequently asked questions about Tazanol

What is Tazanol?

Tazanol (TAZANOLAST) is a tazanolast drug, indicated for Allergic conjunctivitis.

How does Tazanol work?

Tazanolast works by inhibiting the action of a specific enzyme involved in the allergic response.

What is Tazanol used for?

Tazanol is indicated for Allergic conjunctivitis.

What is the generic name of Tazanol?

TAZANOLAST is the generic (nonproprietary) name of Tazanol.

What drug class is Tazanol in?

Tazanol belongs to the tazanolast class. See all tazanolast drugs at /class/tazanolast.

What development phase is Tazanol in?

Tazanol is in Phase 2.

Drug class: All tazanolast drugs
Therapeutic area: All drugs in Immunology
Indication: Drugs for Allergic conjunctivitis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing